Nanobiotix (NBTX) has released an update.
Nanobiotix has made significant strides in its nanoparticle-based therapeutic platforms, highlighted by the transfer of US sponsorship for its pivotal Phase 3 NANORAY-312 study to Janssen, enhancing the potential regulatory pathway for NBTXR3. The company has strengthened its Supervisory Board with key appointments to support long-term growth and reported €53.2 million in cash reserves, providing a financial runway into the fourth quarter of 2025. With upcoming program updates and financial stability, Nanobiotix is poised for continued advancement in the biotech sector.
For further insights into NBTX stock, check out TipRanks’ Stock Analysis page.
